GSK to Invest USD 531 Million in UK, Shift R&D Operations to Cambridge

Published On 2026-07-29 16:47 GMT | Update On 2026-07-29 16:47 GMT

London: British drugmaker GSK said on Tuesday it will invest pound 400 million (USD 531 million) over three years in the country, including moving its R&D operations to Cambridge, as part of its plans to develop medicines faster under new CEO ‌Luke Miels.

GSK's ⁠investment comes ⁠a few months after the U.S. and Britain finalised an agreement aimed at increasing UK medicine prices in line with President Donald Trump's new U.S. pricing policies.

"This investment by GSK is a vote of confidence in British business. A boost for home grown innovation and expertise," British Prime Minister Andy Burnham said in ⁠a statement.

Also Read: USFDA Approves GSK's Cancer Drug Jideytro After USD 10.6 Billion Nuvalent Deal

GSK's ‌decision builds on more than £3 billion in life sciences investment secured in the past 12 months under ⁠the government's Life Sciences Sector Plan, which aims to establish Britain among the top three life sciences economies by 2035.

Rival AstraZeneca announced a £300 million investment in Britain earlier this year, reversing its decision to pause large-scale projects.

GSK said the new 300,000-square-foot site in Cambridge, eastern England, one of Britain's leading life sciences hubs, will support research in its ‌therapeutic focus areas including cancer and respiratory diseases.

Also Read: GSK Halts Cough Drug Camlipixant After Late-Stage Trial Failure

"This investment will accelerate our R&D and help us deliver new, competitive products," Miels said.

As part ⁠of the investment, GSK said it will vacate its R&D site in Stevenage, southern England, by 2029 and also upgrade its nearby facility in Ware, relocating some staff there.

The Cambridge centre will accommodate more than 1,000 scientists, while GSK's global headquarters will remain in London.

GSK invests over £6 billion in R&D annually, with more than £1.5 billion spent in Britain.

Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

sheeba farhat

Sheeba Farhat Joined Medical Dialogues in 2018 to report on the latest Education news. A Graduate of the University of Delhi, she specializes in covering stories related to Medical Education updates. For inquiries or further information, you can reach her at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

GSK to Invest USD 531 Million in UK, Shift R&D Operations to Cambridge

Similar News

CDSCO Cancels Import Registration for IVATHERM Cosmetics Held by Mylan Pharma

Indian Railways to Recruit 120 Pharmacists Under RRB Paramedical Drive 2026

Gland Pharma Wins USFDA Approval for Generic Bridion Injection, Launches Product in US

US Judge Partly Refuses to Dismiss Investor Fraud Suit Against Novo Nordisk Over CagriSema

CDSCO Approves AstraZeneca's Enhertu for Neoadjuvant HER2-Positive Breast Cancer

Odisha Government Plans Direct Recruitment for 1,108 Pharmacy Officer Posts

After NEET, MPSC Drug Inspector Exam Under Scanner Over Alleged Paper Leak